HC Wainwright & Co. Initiates Coverage On Phathom Pharmaceuticals with Buy Rating, Announces Price Target of $28
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield has initiated coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy rating and a price target of $28.
August 09, 2023 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals has been initiated with a Buy rating and a price target of $28 by HC Wainwright & Co.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target of $28 indicates a positive outlook for Phathom Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100